2005. ALZHEIMER. PROJECTES FINANÇATS

Dr Jordi Alberch Vié

Garcia-Martinez JM., Perez-Navarro E., Xifro X., Canals JM., Diaz-Hernandez M., Trioulier Y., Brouillet E,, Lucas JJ., and Alberch J. Bh-only proteins Bid and BimEL are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. Journal of Neuroscience Research, 85(12), 2756-2769, (2007)

Torres-Peraza JF., Giral A., García-Martínez JM., Pedrosa E., Canals JM., and Alberch J. Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodelling of bothpostsynaptic density and NMDA receptor signalling. Neurobiology of Disease, 29, 409-421, (2008)

Gavalda N., Pérez-Navarro E., García-Martínez JM., Marco S., Benito A., and Alberch J. Bax deficiency promotes an up-regulation of BimEL and Bak during striatal and cortical postnatal development, and after excitotoxic injury. Molecular and Cellular Neuroscience 37, 663-672, (2008)

Xifró X., García-Martínez JM., Del Toro D., Alberch J., and Pérez-Navarro E. Calcineurin is involved in the early actívation of nmda-mediated cell death in mutant huntingtin knock-in striatal cells. Journal of Neurochemistry, 105, 1595-612, (2008)

Paoletti P., Vila I., Rife M., Lizcano JM., Alberch J., Gines S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration:the role of p25/cyclin-dependent kinase 5. Journal of Neuroscience, 28(40):10090 -10101, (2008)

Giralt A., Rodrigo T., Martin ED., Gonzalez JR., Mila M., Ceña V., Dierssen M., Canals JM., Alberch J.. Brain Oerived Neurotrophic Factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipaseCy activity and glutamate receptor expression. Neuroscience, 158(4):1234-50, (2008)

Del Toro D., Alberch J., Lazaro-Dieguez F., Martin-Ibañez R., Xifró X., Egea G., Canals JM. Mutant huntingtin impairs post-Golgi trafficking to Iysosomes by delocalizing Optineurin/Rab8 complex from the Golgi apparatus. Molecular Biology of the Cell. 20(5):1478-92, (2009)

Xifró X.., Giralt A., Saavedra A., García-Martínez JM., Díaz-Hernández M., Lucas JJ., Alberch J. and Pérez-navarro E. Reduced calcineurin protein levels and activity in exon-1 mouse models of huntington's disease: role in excitotoxicity. Neurobiology of Disease, 36(3):461-9, (2009)

Saavedra A., García-Martínez JM., Xifró X., Giralt A., Torres-Peraza JF., Canals JM., Díaz-Hernández M., Lucas JJ., Alberch J. and Pérez-navarro E. Ph domain leucine-rich repeat protein phosphatase 1 cntributes to maintain the activation of the pi3k/akt pro-survival pathway in huntington's disease striatum. Cell Death and Differentiation, 17(2):324-35, (2010)

Gines S., Paoletti P. and Alberch J. Impaired trkb-mediated erk1/2 activation in huntington's disease knock-in striatal cells involves reduced p52/p46 shc expression. Journal of Biological Chemistry, 285(28):21537-48, (2010)

Giralt A., Friedman AC., Caneda-Ferrón B., Urbán N., Moreno E., Rubio N., Blanco J., Peterson A., Canals JM. And Alberch J.. Bdnf regulation under gfap promoter provides engineered astrocytes as a new approach for long-term protection in huntington's disease. Gene Therapy, 7(10):1294-1308, (2010)

Del Toro D., Xifró X., Pol A., Humbert S., Saudou F., Canals JM. and Alberch J. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in huntington's disease. Journal of Neurochemistry, 115(1):153-67, (2010)

Dr. Ángel Luis Barco Guerrero

Barco A., Lopez de Armentia M. and Alarcon JM. Synapse-specific stabilization of plasticity processes: The synaptic tagging hypothesis revisited ten years later. Neurosci Biobehav Rev. 32(4):831-51.

Viosca J., Lopez de Armentia M., Jancic D. and Barco A. Enhanced CREB-dependent gene expression increases the excitability of neurons in the basal amygdala and primes the consolidation of contextual and cued fear memory. Learn Mem 16(3): 193-197., (2009)

Viosca J., Malleret G., Bourtchouladze R., Benito E., Vronskava S., Kandel ER. and Barco A. Chronic enhancement of CREB activity in the hippocampus interferes with the retrieval of spatial information. Learn Mem 16(3): 198-209. (2009)

Jancic D., Lopez de Armentia M., Valor LM., Olivares R. and Barco A. Inhibition of cAMP-response element binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cerebral Cortex 19(11): 2535-47. (2009).

Viosca J., Schuhmacher A., Guerra and Barco A. Germ line expression of H-RasG12V causes neurological deficits associated to Costello syndrome. Genes Brain Behav 8(1): 60-71. (2009)

Sanchis-Segura C., Lopez-Atalaya JP. and Barco A. Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition. Neuropsychopharmacology 34(13):2642-54. (2009)

Benito E. and Barco A. CREB's control of intrinsic and synaptic plasticity: Implications for CREB-dependent memory models. Trends Neurosci 33(5): 230-40. (2010)

Valor LM., Jancic D., Lujan R. and Barco A. Ultrastructural and transcriptional profiling of neuropathological misregulation of cAMP-response element binding protein function. Cell Death Differ 17(10):1636-44. (2010)

Valor LM. and Barco A. Hippocampal gene profiling: Toward a systems biology of the hippocampus. Hippocampus. Nov 15, disponible on-line. (2010)

Valor LM., Pulopulos MM., Jimenez-Minchan M., Olivares R., Lutz B. and Barco A. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation, but does not affect cell viability. J Neurosci 31(5): 1652-63. (2011)

Lopez-Atalaya JP., Ciccarelli A., Viosca J., Jimenez-Minchan M., Canals S., Giustteto M. and Barco A. CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement. (sent)

Dr Núria Bargalló Alabart

Donaire A., Carreno M., Bargallo N., Falco C., Maestro I. Ictal-fMRI as a tool to study the seizure neural network. American Epilepsy Society 60th annual meeting. San diego 2006. Epilepsia, 47: 68-68 Suppl. 42006

Donaire A., Bargallo N., Falcón C., Maestro I., Carreno M., Setoain J., Rumià J., Fernández S., Pintor L., Boget T. Identifying the structures involved in seizure generation using sequential analysis of ictal-fMRI data. Available online 1 April 2009. Neuroimage 47 (2009) 173-183

Bargallo N. Functional magnetic resonance: New applications in epilepsy. European Journal of Radiology 67 (2008) 401-408

Maestro I., Donaire A., Bargallo N., Carreno M., Falcon E. Identifing the seizure onset zone from sequential analysis of ictal-frmi data in patients with pharmacoresistant focal epilepsy. 62nd Annual Meeting ofthe American-Epilepsy-Society. DEC 05-09, 2008. Seattle, W A. EPILEPSIA, 49: 395-395 Suppl. 7 (2008)

Donaire A., Falcon C., Carreno M., Bargallo N., Rumia J., Setoain J., Maestro I., Boget T., Pintor L., Agudo R., Falip M., Fernandez S. Sequential analysis of fMRI images: A new approach to study human epileptic networks. Epilepsia. (2009) June 1;1-12.

Donaire A., Bargallo N., Falcón C., Maestro I., Carreno M., Setoain J., Rumia J., Fernández S., Pintor L., Boget T. Identifying the structures involved in seizure generation using sequential analysis of ictal-fMRI data. NeuroImage 47 (2009) 173-183.

Dr Katrin Beyer

Beyer K., Domingo-Sabat M., Humbert J., Carrato C., Ferrer L., Ariza A. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Mar 12; (epub of print) PMID: 18335262. PubMed-as supplied by publisher. Neurogenetics. (2008); 9(3): 163-72

Beyer K., Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neuropathol Exp Neurol. (2007) Nov;66(11):965-74. PMID: 17984679. PubMed-indexed for MEDLINE

Beyer K., Domingo-Sábat M., Lao JI., Carrato C., Ferrer L., Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics. (2008) Feb;9(1):15-23. Epub 2007 Oct 23

Beyer K., Domingo-Sabat M., Ariza A. Molecular pathology of alpha-synucleinopathies. International Journal of Molecular Sciences (IJMS), section Molecular Pathology, special issue on Advances in Molecular Neuropathology (invited review)

Beyer K., Ariza A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Current Medicinal Chemistry. (2008); 15(26):2748-59

Beyer K., Domingo-Sábat M., Lao JI., Carrato C., Ferrer L., Ariza A. Identification and characterization of a new alpha-synuclein isoform and its rale in Lewy body diseases. Neurogenetics. (2008); 9(1):15-23

Beyer K., Domingo-Sàbat M., Santos C., Tolosa E., Ferrer I., Ariza A. The decrease of beta-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain (2010), 133(Pt 12): 3724-33.

Beyer K., Domingo-Sàbat M., Ariza A. Molecular pathology of alpha-synucleinopathies. International Journal of Molecular Sciences (IJMS), section Molecular Pathology, special issue on Advances in Molecular Neuropathology, (invited review), (2009), 10:724-745

Beyer K., Ariza A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Current Medicinal Chemistry. (2008); 15(26):2748-59

Dr Francisco Blanco Vaca

Mälarstig A., Buil A., Souto JC., Clarke R., Blanco-Vaca F., Fontcuberta J., Peden J., Andersen M., Silveira A., Barlera S., Seedorf U., Watkins H., Almsay L., Hamsten A., Soria JM. Indentification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study. Blood (2009); 114. 1417-1422.

Méndez-González J., Rodríguez-Millán E., Julve J., Blanco-Vaca F. Tratamientos vitamínicos para disminuir la concentración de homocisteína: ¿reducen el riesgo de enfermedad cerebrovascular en prevención primaria?. Revista Neurología (2010); 50: 235-244.

Dr Carlos Brotons Cuixart

Brotons C., Soriano N., Moral I., Rodrigo MP., Kloppe P., Rodríguez AI., et al. Ensayo clínico aleatorizado para evaluar la eficacia de un programa integral de prevención secundaria de las enfermedades cardiovasculares en atención primaria: estudio PREseAP. Rev Esp Cardiol. (2011); 64:13-20.

Dr Enric I. Canela Campos

Casadó V., Cortés A., Ciruela F., Mallol J., Ferré S., Lluis C., Canela El., Franco R. Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index. Pharmacol Ther. (2007) 116, 343-54

Franco R., Casadó V., Cortés A., Ferrada C., Mallol J., Woods A., Lluis C., Canela El., Ferré S. Basic concepts in G-protein-coupled receptor homo- and heterodimerization. ScientificWorldJournal. (2007) 7, 48-57 (11/50 Mulldisciplinary Sciencies: Primer Quartil)

Ferrada C., Ferré S., Casadó V., Cortés A., Justinova Z., Sarnes CH., Canela EI., Goldberg SR., Leurs R., Lluis C., Franco R. Interactions between Histamine H3 and Dopamine D2 Receptors and the Irnplications for Striatal Function. Neuropharmacology (2008) Aug. 55 (2) 190-7

Ferrada C., Moreno E., Casadó V., Bongers G., Cortés A., Mallol J., Canela EI., Leurs R., Ferré S., Lluís C, Franco R. Marked changes in signal transduction upon heteromerization of dopamine 01 and histamine H3 receptors. Sr J Pharmacol. (2009) May;157(1):64-75.

Carriba P., Navarro G., Ciruela F., Ferré S., Casadó V., Agnati L., Cortés A., Mallol J., Fuxe K., Canela E.l, Lluís C., Franco R. Oetection of heteromerization of more than two proteins by sequential BRET -FRET. Nat Methods. (2008) Aug;5(8):727-33

Navarro G., Carriba P., Gandía J., Ciruela F., Casadó V., Cortés A., Mallol J., Canela EI., Lluis C., Franco R. Oetection of heteromers formed by cannabinoid CB1, dopamine 02, and adenosine A2A G-protein-poupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal. 2008 Oct 11 ;8: 1088-97.

Ferré S., Quiroz C., Woods AS., Cunha R., Popoli P., Ciruela F., Lluis C., Franco R., Azdad K., Schiffmann SN. An update on adenosine A2A-dopamine 02 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des. (2008);14(15):1468-74. (29/237 Pharmacology and Pharmacy: Primer Quartil)

Franco R., Casadó V., Cortés A., Pérez-Capote K., Mallol J., Canela E., Ferré S., Lluis C. Novel pharmacological targets based on receptor heteromers. Srain Res Rev. 2008 Aug; 58(2):475-82. Epub Jun 20 (review) (2008) (15/231 Neurosciencies: Primer Quartil)

Navarro G., Aymerich MS., Marcellino D., Cortés A., Casadó V., Mallol J., Canela EI., Agnati L., Woods AS., Fuxe K., Lluís C., Lanciego JL., Ferré S., Franco R. Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors. J Biol Chem. (2009) 284, 28058-68. (48/283 Biochemistry and Molecular Biology: primer quartil)

Casadó V., Ferrada C., Bonaventura J., Gracia E., Mallol J., Canela EI., Lluís C., Cortés A., Franco R. Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem Pharmacol. (2009), 78,1456-63. (34/237 Pharmacology and Pharmacy: primer quartil)

Moreno E., Hoffmann H., Gonzalez-Sepúlveda M., Navarro G., Casadó V., Cortés A., Mallol J., Vignes M., McCormick PJ., Canela EI, Lluís C, Moratalla R, Ferré S, Ortiz J, Franco R. Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. J Biol Chem. (2011), 286, 5846-54. (48/283 Biochemistry and Molecular Biology: primer quartil)

Casadó V., Cortés A., Mallol J., Pérez-Capote K., Ferré S., Lluis C., Franco R., Canela EI. GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol Ther. (2009), 124, 248-57. (7/237 Parmacology and Pharmacy: primer decil)

Ferré S., Navarro G., Casadó V., Cortés A., Mallol J., Canela EI., Lluís C., Franco R. G protein-coupled receptor heteromers as new targets for drug development. Prog Mol Biol Transl Sci. (2010), 91, 41-52. (275/283 Biochemistry and Molecular Biology)

Dr Núria Casals Farré

Jauregui O., Sierra A., Carrasco P., Gratacós E., Hegardt FG., Casals N. A new LC- ESI- MS/MS method to measure long-chain acylcarnitine levels in cultured cells. Analytica Chimica Acta 599, 1-6 (2007)

Sierra A., Gratacós E., Carrasco P., Clotet J., Ureña J., Serra D., Asins G., Hegardt FG. and Casals N. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine pamitoyltransferase activity. The Journal of Biological Chemistry 283, 6878-6885 (2008)

Gao S., Keung W., Wang W., Carrasco P., Casals N., Serra D., G. Hegardt F., H. Moran TH. and Lopaschuk GD. Malonyl-CoA Mediates Leptin Hypothalamic Control of Feeding Independent of its inhibition of CPT-1a American Journal of Physiology (accepted publication pending). (2011)

Gao S., Zhu G., Gao X., Wu D., Carrasco P., Casals N., Keung W., Moran TH. and Lopaschuk GD. Important Roles for Brain-specific Carnitine Palmitoyltransferase and Ceramide Metabolism in Leptin Hypothalamic Control of feeding. PNAS (in revision). (2011)

Dr M. Cinta Cid Xutgla

García-Martínez A., Segarra M., Lozano E., Sánchez M., Espígol G., Hernández-Rodriguez J., and Cid MC. Expression of receptor activator of NF-kB (RANK), rank ligand (RANKL), and osteoprotegerin (OPG) in temporal artery lesions from patients with giant-cell arteritis (GCA). Correlation between RANKL expression, neovascularization and intimal hyperplasia. 13th International Vasculitís and ANCA Workshop. Cancun (Mexico). Clin Exp Rheumatol (2007); 25 (suppl 44): S106-S106

Lozano E., Segarra M., Garcia-Martinez A., Corbera-Bellalta M., Espigol G., Hernandez-Rodriguez J. and Cid MC. Downregulation of the endothelin system in giant-cell arteritis lesions. Annual Congress of the American College of Rheumatology. Bastan MA. Arthritis Rheum (2007); 56 (Suppl): S331-S332

García-Martínez A., Lozano E., Segarra M., Hernández-Rodriguez J., Espigol G., Prieto S. and Cid MC. Human temporal artery culture on matrigel: A useful method for preclinical assessment of functional changes after intervention. Annual Congress of the American College of Rhuematotogy. Boston MA. Arthritis Rheum 2007; 56 (suppl): S497

Segarra M., Lozano E., García-Martinez A., Sánchez M., Espigol G., Hernández-Rodríguez J. and Cid MC. Metalloelastase MMP12 expression in giant-cell arteritis lesions. Annual Congress of the American College of Rheumatology. Boston MA. Arthritis Rheum 2007; 56 (suppl): S586

Segarra M., García-Martínez A., Sánchez M., Hernández-Rodríguez J., Lozano E., Grau JM., Cid MC. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis. 2007; 66: 1429-35. IF 5.767

Hernández-Rodríguez J., Font C., García-Martínez A., Espígol-Frigolé G., Sanmartí R., Cañete JD., Grau JM., Cíd MC. Development of ischemic complications in patients with gíant-cell arteritis presenting with apparently isolated polymyalgia rheumatica. Study of a series of 100 patients Medicine (Baltimore) 2007; 86: 233-241. IF 5.167

Cid MC., García-Martínez A., Lozano E., Espígol-Frigolé G., Hernández-Rodríguez J. Management of giant-cell arteritis. Five clinical conundrums. Clin Rheum Dis North Am 2007; 33: 819-834. IF 2.568

Hernández-Rodríguez J., Cid MC. Polyarteritis nodosa. In Svstemic Autoimmune Diseases. Eds R Cervera, y Shonfeld. Humana Press (in press)

Segarra M., García-Martínez A., Sánchez M., Lozano E., Hernández-Rodríguez J. and Cid MC. Gelatinase Expression and Proteolytic Activity in Giant-Cell Arteritis. EULAR Meeting, Barcelona (Spain) Ann Rheum Ois 2007; 66 (supplll): S383-S383

Segarra M., García-Martínez A., Sánchez M., Lozano E., Hernández-Rodríguez J., Cíd MC. Matrix Metalloproteinase (MMP12) Expression in Giant-Cell Arteritis Lesions. EULAR Meeting, Barcelona (Spain) Ann Rheum Ois 2007; 66 (supplll): S383-S384

Lozano E., Segarra M., García-Martinez A., Hernández-Rodríguez J. and Cid MC. Effects of cytokines and growth factors on human temporal artery derived smooth muscle cell biologic functions related to the development of intimal hyperplasia 13th International Vasculitis and ANCA Workshop . Cancun (Mexico). Clin Exp Rheurnatol 2007; 25 (suppl 44): S92-S93

Hernández-Rodríguez J., Segarra M., Sánchez M., Lozano E., García-Martínez A., Grau JM. and Cid MC. Interferon-gamma (IFN gamma) production in inflammatory lesions from patients with giant cell arteritis (GCA). Correlation with TNF alpha and CCL2 (MCP-1) expression. 13th International Vasculitis and ANCA Workshop. Cancun (Mexico) Clin Exp. Rheumatol2007; 25 (suppI44): S105-S105

García-Martínez A., Hernández-Rodríguez J., Segarra M., Lozano E., Espígol G., Grau JM. and Cid MC. Clinical relevance of persistently elevated circulatingf cytokines (TNF alpha and IL-6) in the long term follow-up of patients with giant cell arteritis (GCA). 13th International Vasculitis and ANCA Workshop. Cancun (Mexico) Clin Exp Rheumatol 2007; 25 (suppI44): S105-S105

Lozano E., Segarra M., García-Martínez A., Hernández-Rodríguez J., Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis. 2008; 67: 1581-8.

Lozano E., Segarra M., Corbera-Bellalta M., García-Martínez A., Espigol G., Pla-Campo A., Hernandez-Rodriguez J. and Cid MC. Increased expression of the endothelin system in arteriallesions from patients with giant cell arteritis. Association beetween elevated endothelin plasma levels and the development of ischaemic elements Ann Rheum Dis (2009). 69:434-42 8111

Lozano E., Segarra M., García-Martínez A., Espigol G., Hernández-Rodríguez J. and Cid MC. New therapeutic targets In giant-cell arteritis. Considerations based an the current pathogenic model and the availability of new therapeutic agents.. Clin Exp Rheumatol 2008;26(3 SuppI49):S141-50

Hernández-Rodríguez J., Espinosa G., Cid MC., Cervera R. Diagnóstico de la afectación neurológica central en conectivopatías y vasculitis. A: Enfermedades del Sistema Inmune (IV) Vasculitis y miopías inflamatorias. 10a serie de Medicine. Ediciones Doyma, S1; 2009 (in press)

Hemández-Rodríguez J., Bosch X., Espinosa G., Cervera R., Cid MC. Manejo terapéutico de las vasculitis sistémicas. In Terapéutica Clínica. Ed. Corpus del Rosario (Argentina) 2009 (in press)

Hemández-Rodríguez J., Cid MC. Polyarteritis nodosa. Shoenfeld Y, Cervera R, Gershwin ME (eds.). Diagnostic Criteria in Autoimmune Diseases. Humana Press, Totowa, USA, 2008; pp: 87-92

Corbera M., Lozano E., Espígol-Frigolé G., García-Martínez A., Prieto S., Hernández-Rodriguez J., Ferlin WG., Kosco¬Vilbois M., Cid MC. Functional assessment of the role of interteron gamma (IFNy) in giant-cell arteritis (GCA). ACR 72nd National Meeting. San Francisco, CA. October 2008. Arthitis Rheum 2008;58(9 suppl):S393

García-Martínez A., Prieto S., Arguis P., Hernández-Rodríguez J., Espígol-Frigolé G., Lozano E., Corbella-Bellalta M., Segarra M., Cid MC. Outcome of aortic structural damage (asd) after long-term follow-up of patients with giant-cell arteritis (GCA). Cross-sectional screening of 19 prospectively followed patients. ACR 7200 National Meeting. San Francisco, CA. October 2008. Arthitis Rheum 2008;58(9 suppl):S398

Visvanathan S, Rahman MU, Hoffman GS, Xu S, Garcia Martinez A, Segarra M, Lozano E, Hernandez-Rodríguez J, Cid MC. Tissue and serum levels of selected markers of inflammation and relapse in giant cell arteritis: results from the infliximab phase 2 study. ACR 72nd National Meeting. San Francisco, CA. October 2008. Arthitis Rheum 2008;58(9 suppl):S613

Lozano E., Corbera-Bellalta M., Espígol-Frigolé G., Segarra M., García-Martínez A., Hernández-Rodríguez J., Cid MC. Proinflammatory functions of vascular smooth muscle cells (vsmc) in giant cell arteritis (GCA). ACR 72nd National Meeting. San Francisco, CA. October 2008. Arthitis Rheum 2008;58(9 suppl):S928

Espígol-Frigolé G., Lozano E., Garcia-Martinez A., Segarra M., Corbera M., Hernández-Rodríguez J., Grau JM., Cid MC. IL-17 expression in temporal arteriallesions from patients with giant-cell arteritis (GCA). ACR 72nd National Meeting. San Francisco, CA. October 2008. Arthitis Rheum 2008;58(9 suppl):S929

Baldini M., Maugeri N., Doni A., Ramirez G., Giacomassi C., Prieto-Gonzalez S., Hernandez-Rodriguez J., Cid MC., Di Comite G., Dell’Antonio G., Ammirati G., Bottazzi B., Mantovani A., Rovere-QUerini P., Sabbadini MG., Manfredi AA. Selective up-regulation of the soluble pattern recognition receptor PTX3 in giant-cell arteritis with recent onset optic nerve ischemia. Arthritis Rheum (2011) (accepted, revision pending).

Ramos Casals M., Stone JH., Cid MC., Bosch X. The cryoglobulinaemias. Lancet (2011) (in press)

Alba M., Espígol-Frigolé G., Prieto-González S., Tavera Bahillo I., García-Martínez A., Butjosa M., Hernández-Rodríguez J., Cid MC. Central Nervous System vasculitis: still more questions than answers. Curr Neuropharmacol (2011) (in press)

Alba M., Espígol-Frigolé G., Butjosa M., Prieto-González S., García-Martínez A., Hernández-Rodríguez J., Cid MC. Treatment of large vessel vasculitis. Curr Imunol Rev (2011) (in press)

Hernández-Rodríguez J., Koening KL., Molloy E. B-cell depletion therapy in patients with refractory Wegener’s granulomatosis with head and neck manifestations. Int J Clin Rheumatol (2010); 5 (1): 29-32.

Hernández-Rodríguez J, Hoffman GS, Koening CL. Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol. 2010;22:29-36.

Hernández-Rodríguez J, Cid MC, Espígol-Frigolé G, Bosch X. Treatment of Polymyalgia rheumatica. Archiv Intern Med 2009; 169: 1839-50.

Cid MC., Prieto-González S., Arguis P., Espígol-Frigolé G., Butjosa M., Hernández-Rodríguez J., Segarra M., Lozano E., García-Martínez A. The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodeling at different sites. APMIS Suppl. (2009) Jun;(127):10-20.

Lozano E., Segarra M., García-Martínez A., Espígol-Frigolé G , Hernández-Rodríguez J. , Cid MC. New therapeutic targets in giant-cell arteritis. Clin Exp Rheumatol (2008); 26: S141-S159.

Cid MC., García-Martínez A., Lozano E., Espígol-Frigolé G., Hernández-Rodríguez J. Five clinical conundrums in the management of giant-cell arteritis. Rheum Dis Clin North Am (2007); 33: 819-834.

Cid MC., Hernández-Rodríguez J., Espígol-Frigolé G., Butjosa M., Prieto-González S, García-Martínez A., Grau JM. Small-vessel vasculitis surrounding an uninflammed temporal artery as a diagnostic criteria for polymyalgia rheumatica: comment on the article by Chatelain et al. Arthritis Rheum (2009) 60: 2853-4.

García-Martínez A., Hernández-Rodríguez J., Segarra M., Lozano E., Espígol E., Grau JM., Cid MC. Clinical relevance of persistently circulating cytokines (TNFα and IL-6) in the long-term follow-up of patients with giant-cell arteritis. 72th American College of Rheumatology Scientific Meeting, San Diego CA, 2006.Arthritis Rheum; (2006) ;54 (Suppl):S763.

García-Martínez A., Segarra M., Lozano E., Sánchez M., Espígol G., Hernández-Rodríguez J., Cid MC. Expression of Receptor Activator of NF-κB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in temporal artery lesions from patients with giant-cell arteritis (GCA). Correlation between RANKL expression, neovascularization and intimal hyperplasia. 72th American College of Rheumatology Scientific Meeting, San Diego , CA. 2006. Arthritis Rheum (2006) ;54 (Suppl):S763.

García-Martínez A., Hernández-Rodríguez J., Arguis P., Segarra M., Lozano E., Ramírez J., Lomeña F., Cid M. Development of aortic aneurysm/dilatation during the follow-up of patients with giant-cell arteritis. A prospective study.EULAR 2007.Barcelona. Ann Rheum Dis (2007); 66 (Suppl 11) :377.

Espígol G., Lozano E., Garcia-Martinez A., Segarra M., Hernández-Rodríguez J., Prieto S.,Grau JM., Cid MC. IL-12 P35 , IL12/23p40 and IL-23 P19 Subunit Expression in Temporal Arterial Lesions from Patients with Giant-Cell Arteritis (GCA). 73th American College of Rheumatology Scientific Meeting, Boston 2007. Arthritis Rheum (2007); 56:S497.

Lozano E., Segarra M., García-Martínez A., Sánchez M., Espígol G., Hernández-Rodríguez J., Cid MC. Effect of Imatinib Mesylate (Gleevec) on PDGF-Mediated Human Temporal Artery Smooth Muscle Cell Proliferation, Migration and Matrix Production. Potential Therapeutic Use in Large-Vessel Vasculitis-Related Vascular Occlusion. 73th American College of Rheumatology Scientific Meeting, Boston (2007) Arthritis Rheum 2007 (suppl)

Lozano E., Segarra M., García-Martínez A., Sánchez M., Espígol G., Hernández-Rodríguez J., Cid MC. Effects of Cytokines and Growth Factors on Human Temporal Artery-Derived Smooth Muscle Cell Biologic Functions Related to the Development of Intimal Hyperplasia. 73th American College of Rheumatology Scientific Meeting, Boston (2007) Arthritis Rheum 2007(suppl)

Lozano E., Segarra E., García-Martínez A., Hernández-Rodríguez J., Cid MC. Imatinib mesylate inhibits biologic responses leading to vascular occlusion in giant-cell arteritis. EULAR 2007.Barcelona. Ann Rheum Dis (2007) (suppl)

Corbera-Bellalta M., Lozano E., Garcia-Martinez A., Espígol-Frigole G., Prieto S., Butjosa M., Hemandez-Rodriguez J., Cid MC. Changes in inflammatory-mediators induced by Glucocorticoids in cultured human temporal arteries from patients with giant-cell arteritis (GCA). 74th American College of Rheumatology Scientific Meeting, San Francisco, CA 2008. Arthritis Rheum (2008) 58 (9): S929-S929.

García-Martínez A., Arguis P., Prieto S., Espígol-Frigolé G., Butjosa M., Lozano E., Corbera-Bellalta M., Segarra M., Hernández-Rodríguez J. and Cid MC. Outcome of aortic structural damage after long-term follow-up of patients with giant-cell arteritis: cross-sectional screening of 24 patients. 14th Vasculitis and ANCA Workshop Lund/Copenhagen (2009). APMIS 2009;117 (Suppl 127):86.

Espígol-Frigolé G., Gómez-Choco M., Obach V., Sanroman L., Prieto S., Argelich R., Grau JM. and Cid MC. Percutaneous transluminal angioplasty of internal carotid and vertebral arteries in giant cell arteritis (GCA): report of two cases. 14th International Vasculitis and ANCA Workshop. Lund, June 2009. APMIS (2009) (suppl).

Prieto S., Arguis P., Espígol-Frigolé G., Lozano E., Butjosa M., Corbera-Bellalta M., Grau JM., Hernández-Rodríguez J. and Cid MC. Aortic involvement in patients with newly diagnosed giant cell arteritis (GCA). A prospective study using computed tomography (CT) angiography. 14th International Vasculitis and ANCA Workshop. Lund, June 2009. APMIS (2009) (suppl).

Corbera-Bellalta M., Lozano E., Garcia-Martinez A., Espígol-Frigole G., Prieto S., Butjosa M., Planas-Rigol E., Hemandez-Rodriguez J., Cid MC. Changes in gene expression induced by blocking Interferon gamma (IFNg) in ex-vivo cultured arteries from patients with Giant-Cell Arteritis (GCA). 75th American College of Rheumatology Scientific Meeting, Philadelphia PA. 2009.Arthritis Rheum (2009), 60 Suppl 10 :S183.

Prieto-González S., Arguis P., García-Martínez A., Espígol-Frigolé G., Butjosa M., Tavera I., Grau J., Hernández-Rodríguez J. and Cid MC. Hospital Clínic. Aortic involvement in patients with newly diagnosed giant cell arteritis (GCA). A prospective study using computed tomography (CT) angiography. 75th American College of Rheumatology Scientific Meeting, Philadelphia, October 2009. Arthritis Rheum (2009), 60 (Suppl).

Prieto-González S., Arguis P., García-Martínez A., Espígol-Frigolé G., Butjosa M., Tavera I., Grau JM., Hernández-Rodríguez J., Cid MC. Aortic involvement in patients with newly diagnosed giant cell arteritis (GCA). A prospective study using computed tomography (CT) angiography. Annual European Congress of Rheumatology EULAR, Roma, June 2010. Ann Rheum Dis (2010); 69(Suppl).

García-Martínez A., Arguis P., Prieto S., Hernández-Rodríguez J., Espígol G., ButjosaM., Corbera M., Cid MC. Outcome of aortic structural damage after long-term follow-up of patients with giant-cell arteritis. Cross-sectional screening of 29 prospectively followed patients. Annual European Congress of Rheumatology EULAR, Roma, June 2010. Ann Rheum Dis (2010); 69(Suppl3):689.

Corbera-Bellalta M., García-Martínez A., Planas-Rigol E., Lozano E., Segarra M., Espígol-Frigolé G., Hernández-Rodríguez J., Tavera I., Cid MC. Effect of glucocorticoids on gelatinase (MMP-2 and MMP-9) expression in giant-cell arteritis (GCA) using an ex-vivo temporal artery culture model. 75th American College of Rheumatology Scientific Meeting, Atlanta GA. 2010. Arthritis Rheum (2010). (suppl).

Planas-Rigol E., Corbera-Bellalta M., Lozano E., Butjosa M., Prieto-González S., Hernández-Rodríguez J., Segarra M., and Cid MC. Endothelin-1 (ET-1) Induces Collagen Type I and Type III Production by Temporal Artery-Derived Myointimal Cells. A Mechanism Potentially Leading to Intimal Hyperplasia in Giant-Cell Arteritis (GCA). 75th American College of Rheumatology Scientific Meeting, Atlanta GA. 2010. Arthritis Rheum (2010) (suppl)

Alba MA., Garcia-Martinez A., Espigol-Frigole G., Tavera I., Butjosa M., Prieto-Gonzalez S., Hernandez-Rodriguez J. and Cid MC. Treatment with Angiotensin Converting Enzyme Inhibitors(ACEI) or Angiotensin II Receptor Antagonists (ARA) Is Associated with Higher Frequency of Ischemic Complications but Better Response to Therapy in Patients with Giant-Cell Arteritis (GCA). 75th American College of Rheumatology Scientific Meeting, Atlanta GA. 2010. Arthritis Rheum (2010) (suppl).

Dr Jaume Coll Cantí

Sarmiento J., Perez-Moltó H., Coll J., Vitoria S., Dura MJ., Klamburg J., Alvarez R. Critical illnes myopathy (CIM):early detection and outcome. Intensive Care Medicine (2009); 35:S137

Coll Cantí J., Álvarez Ramo R., Pérez Moltó H., Ojanguren Saban I.,Martínez Cáceres EM., Misis del Campo M., Dura Mata MJ., Vitoria Rubio S., Sarmiento Martínez X., Serichol Puig M., Klamburg Pujol J. Miopatía de la UCI. Neurología (2008) ; 23(10):617

Coll Cantí J., Dura Mata MJ., Pérez Moltó H., Álvarez Ramo R., Ojanguren Sabán I., Sarmiento Martínez X., Rubio V., Del Campo M., Sericchol M., Klamburg J. Pronòstic dels pacients amb miopatia de la UCI. Rev Neurol (2009); 48:548

Sarmiento X.; Perez-Molto H.; Coll-Canti J. Early detection, outcome and factors associated to critical illness myopathy. Intensive Care Medicine (2010), 36:S212

Dr Bru Cormand Rifà

Dr José Manuel Fernández Fernández

Cuenca-León E., Corominas R., Fernandez-Castillo N., Volpini V., Del Toro M., Roig M., Macaya A., Cormand B. Genetic analysis of 27 Spanish patients with hemiplegic migraine, basilar-type migraine and childhood periodic syndromes. Cephalalgia. (2008), 28(10):1039-47. Clinical Neurology

Cuenca-León E., Corominas R., Montfort M., Artigas J., Roig M., Bayés M., Cormand B., Macaya A. Familial Hemiplegic Migraine: Linkage to Chromosome 14q32 in a Spanish Kindred. Neurogenetics (2009) 10:191-198. Clinical Neurology

Corominas R., Ribasés M., Cuenca-León E., Cormand B., Macaya A. Lack of association of hormone receptor polymorphisms with migraine. Eur J Neurol. (2009) 16: 413-415 . Clinical Neurology

Corominas R., Sobrido MJ., Ribases M., Cuenca-Leon E., Blanco-Arias P., Narberhaus B., Roig M., Leira R., Lopez-Gonzalez J., Macaya A., Cormand B. Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet. B Neuropsychiatr Genet (2010), 153B (1) 177-84, 92 Genetics & Heredity

Serra SA., Fernandez-Castillo N., Macaya A., Cormand B., Valverde MA., Fernández-Fernández JM. The Hemiplegic Migraine associated Y1245C mutation in CACNA1A results in a gain of channel function due to its effect on the voltage sensor and G-protein mediated inhibition. Pflugers Archiv-Eur J Physiol (2009) 458 (B):489-502 H3 Physiology

Cuenca-León E., Banchs I., Serra SA., Latorre P., Fernández-Castillo N., Corominas R., Valverde MA., Volpini V., Fernández-Fernández JM., Macaya A., Cormand B. Late-Onset Episodic Ataxia Type 2 associated with a novel missense CACNA1A mutation. J Neurol Sciences 15:280 (2009) 10-14: (1-2) Q2 Clinical Neurology

Serra SA., Cuenca-León E., Llobet A., Rubio-Moscardo F., Plata C., Carreño O., Fernández-Castillo N., Carominas R., Valverde MA., Macaya A., Cormand B., Fernández-Fernández JM. A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers secretion efficiency: relevance to migraine phenotype. Proceedings Natl Aead Seí USA, 455 (2009) 105-109

Corominas R., Ribasés M., Cuenca-León E., Narberhaus B., Serra SA., del Toro M., Roig M., Fernández¬Fernández JM., Macaya A., Cormand B. Contribution of syntaxin 1A to the genetic susceptibility to migraine: a case-control association study in the Spanish population. Neurosc Letters (2009), 455 (2): 105-9 Q3 Neurosciencies

Corominas R., Sobrido MJ., Cuenca-León E., Blanco P., Narberhaus B., del Toro M., Leira R., López J., Ribasés M., Macaya A., Cormand B. Association study of migraine and 19 candidate genes involved in serotoninergic neurotransmission in a Spanish population. European Human Genetics Conference 2008, May 31-June 3, Barcelona, Spain. Eur J Hum Genet 16 (suppl 2):329

Cuenca-León E., Corominas R., Montfort M., Artigas J., Roig M., Bayés M., Cormand B., Macaya A. Familial hemiplegic migraine: linkage to chromosome 14q32 in a large Spanish pedigree. European Human Genetics Conference 2008, May 31-June 3, Barcelona, Spain. Eur J Hum Genet 16 (suppl 2):332-313

Serra SA., Fernandez-Castillo N., Macaya A., Cormand B., Valverde MA. and Fernández-Fernández, JM. The Hemiplegic Migraine associated Y1245C mutation in CACNA1A results in a gain of channel function due to its effect on the voltage sensor and G-protein mediated inhibition. Pflugers Archiv - European Journal of Physiology 2009 (in press)

Cuenca-León E., Banchs l., Serra SA., Latorre P., Fernandez-Castillo N., Corominas R., Valverde MA., Volpini V., Fernández-Fernández JM. Macaya A., and Cormand B. Late-Onset Episodic Ataxia Type 2 associated with a novelloss-of-function mutation in the CACNA1A gene. Journal of The Neurological Sciences. 2009 (in press)

Fernández-Fernández JM., Andrade YN., Arniges M., Fernandes J., Plata C., Rubio-MoscardO F., Vázquez E. and Valverde MA. Functional coupling of TRPV4 cationic channel and large conductance, calcium-dependent potassium channel in human bronchial epithelial celllines. Pflügers Archiv - European Journal of Physiology 457(1) 149-159 (2008) Q2 Phisiology

Fernandes J., Lorenzo IM., Andrade YN., Garcia-Elias A., Serra SA., Fernández-Fernández JM. and Valverde MA. IP3 sensitizes TRPV4 channel to the mechano- and osmotransducing messenger 5'- 6' epoxyeicosatrienoic acid. Journal of Cell Biology 181(1) 143-155 (2008) (Republished in Journal ol General Pysiology (2008) 131(5): 12 DI Cell Biology

Corominas R., Ribases M., Camiña M., Cuenca-León E., Pardo J., Boronat Sobrido MJ., Cormand B., Macaya A.Two-stage case-control association study of dopamine-related genes and migraine. BMC Medical Genetics (2009), 10:95 BioMed Central. Q2 Genetics & Heredity

Tian W., Fu Y., García-Elías A., Fernández-Fernández JM., Vicente R., Kramer PL., Klein RF., Hitzemann R., Orwoll ES., Wilmot B., McWeeney S., Valverde MA., Cohen DM. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 genes is associated with human hyponatremia. Proc Natl Acad Sci USA. 2009; 106(33):14034-14039

Serra SA., Cuenca-León E., Llobet A., Rubio-Moscardo F., Plata C., Carreño O., Fernández-Castillo N., Corominas R., Valverde MA., Macaya A., Cormand B., Fernández-Fernández JM. A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. Proc Natl Acad Sci U S A. 2010; 107(4):1672-7

Dr Mara Dierssen Sotos

Dr José Ramon Naranjo Orovio

Dr Salvador Martínez Pérez

Gallego X., Murtra P., Zamalloa T., Canals JM., Pineda J., Amador A. Increased opioid dependence in a mouse model of panic disorder. (sent Frontiers in Neuroscience)

Dierssen M., Herault Y., and Estivill X. Aneuploidy: from a Physiological Mechanism of Variance to Down Syndrome Physiologic al Reviews 89:887-920, (2009)

Giralt A., Rodrigo T., Martín ED., González JR., Ceña V., Dierssen M., Canals JM., Alberch J. Brain Derived Neurotrophic Factor modulates the severity of cognitive alterations induced by mutant huntingtin through changes in phospholipaseCy activity and glutamate receptor expression. Neuroscience. 18;158(4):1234-50. (2009)

Arqué G., Fotaki V., Fernández D., Martínez de Lagrán M., Arbonés ML., Dierssen M. Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for Dyrk1A. PLoS ONE 3(7): e2575. (2008)

Azkona G., Amador-Arjona A., Obradors-Tarragó C., Varea E., Arqué G., Pinacho R., Fillat C., de la Luna S., Estivill X., Dierssen M. Characterization of a mouse model overexpressing the Beta-site APP-cleaving enzyme 2, BACE2, reveals a new role for Bale 2. Genes Brain and Behavior (2010) 9:160-72

Basson MA., Echevarria D., Petersen Ahn C., Sudarov AM., Jáyner AL., Mason IJ., Martinez S., Martin GR. Spécific regions within the embryonic midbrain and cerebelLum require different levels of FGF signaling during development. Development, 135:889-898 (2008)

Perez-Balaguer A., Puelles E., Wurst W., Martinez S. Shh dependent and independent maintenance of basal midbrain. Mech Dev. (2009) 126:301-313.

Benavides-Piccione R., Dierssen M., Ballesteros-Yáñez I., Martínez de Lagrán M., Arbonés ML., Fotaki V., De Felipe J., Elston GN. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol Dis. (2005), 20: 115-22.

Ferrer I., Barrachina M., Puig B., Martínez de Lagrán M., Martí E., Avila J., Dierssen M. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis. (2005), 20: 392-400.

Martinez de Lagran M., Bortolozzi A., Millan O., Gispert JD., Gonzalez JR., Arbones ML., Artigas F., Dierssen M. Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A(+/-). Genes Brain Behav. (2007), 6: 569-78.

Arqué G., de Lagrán MM., Arbonés ML., Dierssen M. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. Neurobiol Dis. (2009), 36: 312-9.

Lott IT., Dierssen M., Down syndrome: Neurological Complications and Cognition. The Lancet Neurology, (2010), 9: 623-33.

Fillat C., Diersen M., Martinez de Lagran M., Altafaj X. Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. CNS & Neurolog Disord-Drug Targets, (2010), 9: 429-38.

Azkona G., Levannon D., Groner Y., Dierssen M. In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids. (2010), 39: 1571-80.

Toiber D., Azkona G., Ben-Ari S., Torán N., Soreq H., Dierssen M. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol Dis. (2010), 40: 348-59.

Martínez de Lagrán M., Benavide-Piccione R., Ballesteros-Yanez Y., Calvo M., Morales M., Fillat C., De Felipe J., Ramakers GJ., Dierssen M. Single overexpression of Dyrk1A recapitulates the dendritic abnormalities of Down syndrome patients. (Submited to Cerebral Cortex)

Moreno-Bravo JA., Perez-Balaguer A., Martinez S., de Puelles E.. Dynamic expression patterns of Nkx6.1 and Nkx6.2 in the developing mes-diencephalic basal plate. Developmental Dynamics (2010), 239:2094-2101

Dr Josep Enric Esquerda Colell

Dr Joan Serratosa Serda

Dr Jerònia Lladó Vich

Dr Carles Solsona Sancho

Dr Ronald William Oppenheim

Casanovas A., Hernández S., Tarabal O., Rosselló J., Esquerda JE. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis. Journal of Comparative Neurology 506:75-92 (2008)

Mir M., Tolosa L., Asensio VJ., Lladó J., Olmos G. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. Cellular Siqnallinq, (2008) (sent)

Solsona C. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. Meeting report of European ALS Consortium (EALSC): 6th European ALS congress research workshop and young investigators' meeting. Octubre de 2008, 9(5):318-20

Oppenheim RW., Calderó J., Cuitat D., Esquerda J., McArdle JJ., Olivera BM., Prevette D., Teichert RW. The rescue of developing avian motoneurons from programmed cel! death by a selective inhibitor of the fetal muscle-specific nicotinic acetylcholine receptor. Developmental Neurobiology. 68:972-980 (2008)

Calderó J., Brunet N., Ciutat D., Hereu M., Esquerda JE. Development of microglia in the chick embryo spinal cord: implications in the regulation of motoneuronal survival and death. Journal of Neuroscience Research (2009) 87:2447-2446

Brunet N., Tarabal O., Esquerda J., Calderó J. Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord. Journal of Comparative Neurology (2009) 516: 277-290

Hernández S., Casanovas A., Piedrafita L., Tarabal O., Esquerda JE. Neurotoxic . species of misfolded 8001 G93A that can be recognized by antibodies against the P2X4 subunit of the A TP receptor accumulate in damaged neurons of transgenic animal models of amyotrophic lateral sclerosis. Journal of Neurochemistry (2009) J:Neuropathol Exp. Neurol. 69:1767-187

Tusell JM., Ejarque-Ortiz A., Mancera P., Sola C., Saura J., Serratosa J. Upregulation of p21c,P1 in Activated Glial Cells. Glia, 57: 524-534 (2009)

Tolosa L., Mir M., Asensio VJ., Olmos G., Lladó J. Vascular endothelial growth factor protects spinal motoneurons against glutamate-induced excitotoxicity vía phosphatidylinositol 3-kinase. Journal of Neurochemistry 105: 1 080-1 090 (2008)

Mir M., Tolosa L., Asensio VJ., Lladó J., Olmos G. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. Journal of Neuroimmunology 204:101-109 (2008)

Tolosa L., Mir M., Olmos G., Lladó J. Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38MAPK inhibition. Neuroscience 158: 1348-1355 (2009)

Hernandez S., Casanovas A., Piedrafita L.,Tarabal O., Esquerda JE. Neurotoxic Species of Misfolded 5001 G93A Recognized by Antibodies Against the P2X4 Subunit of the ATP Receptor Accumulate in Damaged Neurons of Transgenic Animal Models of Amyotrophic Lateral Sclerosis. J Neuropathol. Vol. 69. No. 2 February (2010) pp. 176-187

Calderó J., TarabaI O., Casanovas A., Ciutat D., Casas C., Lladó J., Esquerda JE. Excitotoxic Motoneuron Disease in Chick Embryo Evolves With Autophagic N eurodegeneration and Deregulation of N euromuscular Innervation. Journal of Neuroscience Research 85:2726-2740 (2007)

Calderó J., Brunet N., Tarabal O., Piedrafita L., Hereu M., Ayala V., Esquerda JE. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 165:1353-1369. (2010)

Hernández S., Texidó L., Calderó J., Ciutat D., Piedrafita L., Casanovas A., Blasi J., Solsona C., Povedano M., Rojas R., Illa I., Caress J., Prevette D., Oppenheim RW., Milligan C., Esquerda JE. Increased intramuscular nerve branching and inhibition of programmed cell death of chick embryo motoneurons by immunoglobulins from patients with motoneuron disease. J Neuroimmunol. 229:157-168. (2010)

Valente T.., Mancera P., Tusell JM., Serratosa J., Saura J. C/EBPβ expression in activated microglia in amyotrophic lateral sclerosis. Neurobiology of Aging (submitted) (2011)

Mir M.; Tolosa,L..; Asensio,VJ.; Lladó J.; Olmos G. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. Journal of Neuroimmunology 204:101-109 (2008)

Mir M.; Asensio VJ., Tolosa L.; Gou-Fabregas M.; Soler RM.; Lladó J.; Olmos G. Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative stress and motoneuron death in rat spinal cord embryonic explants. Neuroscience 162:959-971. (2009)

Tolosa L.; Caraballo-Miralles V.; Olmos G.; Lladó J. TNF-α potentiates glutamate-induced spinal cord motoneuron death via NF-κB. Molecular and Cellular Neuroscience 46:176-186. (2011)

Texidó L., Hernández S., Martín-Satué M., Povedano M., Casanovas A., Esquerda JE., Marsal J., Solsona C. Sera from amyotrophic lateral sclerosis patients induce the non-canonical activation of NMDA receptors “in vitro”. Neurochemistry International, (submitted) (2011)

Texidó L., Martín-Satué M., Alberdi E., Solsona C., Matute C Amyloid-β peptide oligomers directly activate NMDA receptors Abbreviated title: Amyloid-β activates NMDA receptors. Cell Calcium, (in press) (2011)

Dra. Lydia Giménez Llort

Dra. Coral Sanfeliu Pujol

Dr. Björn Johansson

Guitart-Masip M., Johansson B., Fernández-Teruel A., Cañete T., Tobeña A., Terenius L., and Gimenez-Llort L. Divergent anatomical pattern of D1 and D3 binding and dopamine and cyclic amp regulated Phosphoprotein of 32 kDa mRNA expression in the roman rat strains: implications for durg eddiction. Neuroscience 142 (2006) 1231-1243

Manuel I., Cañete T., LaFerla FM., Giménez Llort L., Rodríguez-Puertas R. Regulación del acople a proteinas GI/O de receptores de galanina y muscarínicos en áreas límbicas de ratones Triple Transgénicos 3XtG-AD, Modelo de Enfermedad de Alzheimer (in press) (2008)

España J., Giménez-Llort I., Valero J., Miñano A., Rábano A., Rodriguez-Alvarez J., Laferla FM., Saura CA. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in alzheimer's disease transgenic mice. Biol psychiatry. (2010), 67(6):513-521.

Solé-Domènech S., Johansson B., Schalling M., Malm J., Sjövall P. Analysis of opioid and amyloid peptides using time-of-flight secondary ion mass spectrometry. Anal. Chem. (2010), 82:1964-1974

García-Matas S., Vera N., Ortega Aznar A., Marimon JM., Adell A., Planas AM., Cristòfol R., Sanfeliu C. In vitro and in vivo activation of astrocytes by amyloid b is potentiated by pro-oxidant agents. J alzheimers dis. 2010, 20:229-245 (2010)

Ratia M., Giménez-Llort I., Camps P., Muñoz-Torrero D., Clos V. Behavioural effects and regulation of pkcα and mapk by huprine x in middle aged mice. Pharmacol biochem behav. (2010), 95(4):485-493.

Giménez-Llort I., García Y., Buccier K. ,. Revilla S., Suñol C., Cristofol R., Sanfeliu C. Gender-specific neuroimmunoendocrine response to treadmill exercise in 3xtg-ad mice. Int j alzheimers dis. (2010):128354.

García Y., López-Ramos JC., Giménez-Llort I., Revilla S., Guerra R., Gruart A., Laferla FM., Cristòfol R., Delgado-García JM., Sanfeliu C. Physical exercise protects against alzheimer's disease in 3xtg-ad mice. J alzheimers dis. (2011) feb 1. (epub ahead of print)

Arranz L., De Castro NM., Baeza I., Giménez-Llort I., De la fuente M. Effect of environmental enrichment on the neuroimmunoendocrine aging of male and female triple-transgenic 3xtg-ad mice for alzheimer’s disease. J alzheimers dis. (2011). (accepted)

Cañete T., Blazquez G.,Tobeña A., Fernandez-Teruel A., Gimenez-Llort I. Early postnatal handling attenuates excessive behavioral disinhibition/hyperactivity and spatial learning deficits in 3xtg-ad mice for alzheimer’s disease. (in preparation)]

Giménez-Llort L., Ramirez-Boix P., Torres-Lista V., López-Ramos JC., García Y., Laferla FM., Delgado-García JM., Sanfeliu C. Modeling neuropsychiatric symptoms of alzheimer's disease: neophobia, anxiety and aggressiveness in 3xtgad mice at advanced stages of the disease. (in preparation)

González B., Ramírez-Boix P., Almolda B., Laferla FM., Castellano B., Giménez-Llort I. Beneficial effects of a permament family structure: behavioural and neuropathological studies in triple transgenic 3xtgad mice for alzheimer's disease. (in preparation)

Dr Ernest Giralt Lledó

Grillo-Bosch D., Carulla, N., Cruz M., Sánchez L., Madurga S., Rabanal F., Giralt E. Retro-enantio N-methylated peptides as p-amyloid aggregation inhibitors. Chem Medchem 4, 1488-1494 (2009)

Carulla N., Zhou M., Arimon M., Gairí M., Giralt E., Robinson CV., Dobson CM. Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. ProceecÜngs ofthe National Academy of Sciences, USA 106, 7828-7833 (2009)

Carulla N., Zhou M., Giralt E., Robinson CV., Dobson CM. Structure and Intermolecular Dynamics of Aggregates Populated during Amyloid Fibril Formation Studied by Hydrogen/Deuterium Exchange. Acc. Chem. Res. 43, 1072-1079 (2010)

Sánchez L., Madurga S., Pukala T., Vilaseca M., López-Iglesias C., Robinson CV., Giralt E., Carulla N. Aβ40 and Aβ42 exhibit distinct molecular recycling properties. JACS (in press).

Arimon, M., Sanz, F., Giralt, E., Carulla, N. Lateral growth of amyloid-β42 fibrils studied by differential labeling with gold nanoparticles. (submitted)

Dr Berta González de Mingo

Almolda B., Costa M., Montoya M., González B., Castellano B. CD4 microglial expression correlates with spontaneous clinical improvement in the acute Lewis rat EAE model. J Neuroimmunol., 209: 65-80 (2009)

Montero Domínguez M., González B., Zimmer J. Neuroprotective effects of the anti-inflammatory compound triflusal on ischemia-like neurodegeneration in mouse hippocampal slice cultures occur independent of microglia. Experimental Neurology 218: 11-23 (2009)

Almolda B., González B., Castellano B. Activated microglial cells acquire an immature dendritic cell phenotype and may terminate the immune response in an acute model of EAE. J Neuroimmunol. 223:39-54 (2010)

Almolda B., González B., Castellano B. Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front Biosci.1;16:1157-71 (2011)

Almolda B., Guaza C., Acarin L., Giralt M., Hidalgo J., Docagne F., Castellano, Gonzalez B. The treatment with triflusal in Theiler´s virus infected mice resulted in significant improvement of motor functions, changes in glial cells and modulation of pro-inflammatory mediators. J. Neuroinflammation, (in revision)

Almolda B., Costa M., Montoya M., González B., Castellano B. Presence of specific subpopulations of T-helper lymphocytes correlates with the different phases of acute EAE. PLoS ONE, (in revision)

Dr Joan J. Guinovart Cirera

Dr Santiago Rodríguez de Córdoba

Dr Pascual Sanz Bigorra

Vilchez D,. Ros S., Cifuentes D., Pujadas Ll., Valles J., Garcia-Fojeda B., Criado-Garcia O., Fernandez-Sanchez E., Medraño M., Dominguez J., Garcia-Rocha M., Soriano E., Rodriguez de Cordoba S., Guinovart JJ. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nature Neuroscience 10 (11), 1407-1413 (2007)

Vilchez D,. Ros S., Cifuentes D., Pujadas Ll., Valles J., Garcia-Fojeda B., Criado-Garcia O., Fernandez-Sanchez E., Medraño M., Dominguez J., Garcia-Rocha M., Soriano E., Rodriguez de Cordoba S., Guinovart JJ. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. News and views Nature Neuroscience, 10 (11), 1341-1342 (2007)

Vilchez D,. Ros S., Cifuentes D., Pujadas Ll., Valles J., Garcia-Fojeda B., Criado-Garcia O., Fernandez-Sanchez E., Medraño M., Dominguez J., Garcia-Rocha M., Soriano E., Rodriguez de Cordoba S., Guinovart JJ. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nature Clinical Practice Neurology, 4 (2), 62-63 (2008)

Solaz-Fuster MD., Gimeno-Alcañiz JV., Ros S., Fernandez-Sanchez ME., Garcia-Fojeda B., Garcia OC., Vilchez D., Dominguez J., Garcia-Rocha M., Sanchez-Piris M., Aguado C., Knecht E., Serratosa J., Guinovart JJ., Sanz P., De Cordoba SR. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase' pathway. Hum Mol Genet, 17 (5), 667 - 678 (2008)

Vernia S., Solaz-Fuster MC., Gimeno-Alcañiz JV., Rubio T., García-Haro L., Foretz M., Rodríguez de Córdoba S. and Sanz P. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-PP1, holoenzyme and accelerates its downregulation by the laforin-malin complex. J Biol Chem (2009) . 284:8247-8255

Vernia S., Rubio T., Heredia M., Rodríguez de Córdoba S., and Sanz P. Laforin, responsible of Lafora disease, protects from endoplasmic reticulum stress by preserving ubiquitin-proteasomal function. J Biol Chem. (2009) (in revision)

Vernia S., Rubio T., Heredia M., Rodríguez de Córdoba S., and Sanz P. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. Plos One. 4(6):e5907. (2009). Índex d’impacte (JCR, 2007)

Vílchez D., Rodríguez de Córdoba S., Guinovart JJ. Enfermedad de Lafora: epilepsia y regulación del metabolismo de glucógeno por laforina y malina. Monografía XXV Avances en Neurociencia: Neurotransmisores y Patologías Nerviosas. (Ed. Real Academia Nacional de Farmacia). Capítulo 11 pp: 315-345 (2009).

Dr Juan Carlos Izpisua Belmonte

Dr Joana Visa Esteve

Dr Fred H. Gage

Raya A., Rodríguez-Piza l., Consiglio A., Guenechea G., Vassena R., Navarro S., Barrero MJ., Tiscomia G., Garreta E., Aasen T., Veiga A., Verma IM., Bueren J., Izpisúa Belmonte JC. Generation of disease-free hematopoietic progenitors from Fanconi anemia-specific índuced pluripotent stem cells. Nature, (3rd revision)

Aasen T., Raya A., Barrero MJ., Garretta E., Consiglio A., Gonzales F., Vassena R., Bilic J., Edel M., Tiscomia G., Pekarik V., Boue S., Belmonte JC. Generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnology, 26(11): 1276-84. (2008)

Raya A., Arán B., Rodríguez-Piza l., ConsiglioA., Barri P., Veiga A., Izpisúa Belmonte JC. Generation of cardiomyocytes from new human embryonic stem celllines derived from poor-quality blastocysts. Cold Spring Harbor Symposia on Quantitative Biology, Nov 26. (2008). 73: 127-35

Consiglio A., Sanchez A., Raya A., Gomez Isla T., Belmonte JC. Impaired neurogenesis in the adult hippocampus of a double mutant APP/tau transgenic mice (in preparation)

Raya A., Rodríguez-Pizà I., Consiglio A., Guenechea G., Vassena R., Navarro S., Barrero M.J., Tiscornia G., Garreta E., Aasen T., Veiga A., Verma I.M., Bueren J., Izpisúa Belmonte J.C. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature, 460(7251):53-9. Epub 2009 May 31. (2009)

Aasen T., Raya A., Barrero M.J., Garretta E., Consiglio A., Gonzales F., Vassena R., Bilic J., Edel M., Tiscornia G., Pekarik V., Boue S., Belmonte JC.. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnology, 26(11): 1276-84. (2008)

Rodríguez-Pizà I., Richaud-Patin Y., Vassena R., González F., Barrero MJ., Veiga A., Raya A., Belmonte JC. Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells. Jan; 28(1):36-44. (2010)

M Lie DC., Moore L., Nakashima K., Asashima M., Gage FH. Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nat Neurosci.12(9):1097-105. (2009)

Jessberger S., Clark RE., Broadbent NJ., Consiglio A., Clemenson GD., Lie CD., Squire LR., and Gage FH. Dentate gyrus-specific knockdown of adult neurogenesis identifies a role for newborn neurons in hippocampus-dependent learning and memory. Learning and Memory 29;16(2):147-54. (2009)

Dr. Jaume Kulisevsky Bojarski

Kulisevsky J., Gomez-Anson B., Pagonabarraga J., et al. Proton spectroscopy as a marker of cortical reorganization in Parkinson's disease with executive dysfunction. Annual Meeting of the American Academy of Neurology. Chicago, May 2008. Neurology (2008); 70: A438.

Pagonabarraga J., Llebaria G., Kulisevsky J., et al. Combined use of 3T proton spectroscopy, DTI and VBM for capturing cortical changes in Parkinson's disease with cognitive dysfunction: A preliminary study. 12th International Congress of Parkinson’s Disease and Movement Disorders. Chicago, June 2008. Mov Disord (2008); 23 (6): S92-S92)

Pagonabarraga J., Llebaria G., Gómez-Ansón B., López-Mourelo O., Rotger R., Delfino M., Kulisevsky J. Cortical” items in the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) correlate with hippocampal volume atrophy in Parkinson´s disease with dementia. 61th Annual Meeting of the American Academy of Neurology. Seattle, April 2009. Neurology (2009); 72 (11): A166-167.

Pagonabarraga J., Llebaria G., Corcuera I., Pascual-Sedano B., García-Sánchez C., Martinez-Horta S., Gironell A., Vives Y., Gómez-Anson B., Kulisevsky J. Pattern of cortical thickness associated with cognitive impairment and dementia in Parkinson's disease. 14th International Congress of Parkinson’s Disease and Movement Disorders. Mov Disord (2010); 25 (7): S322-S323.

Pagonabarraga J., Llebaria G., Soriano-Mas C., Pascual-Sedano B., López-Solà M., Gironell A., Pujol J., Kulisevsky J. Gray Matter Changes Associated with Early Hallucinations in Parkinson's Disease. 62th Annual Meeting of the American Academy of Neurology. Toronto, April 2010. Neurology (2010); 74: A236.

Llebaria G., Pagonabarraga J., Martínez-Corral M., García-Sánchez C., Pascual-Sedano B., Gironell A., Kulisevsky J. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord. (2010) Dec 15;25(16):2785-91. IF 4,014

Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., Burn D., Barone P., Pagonabarraga J., Allcock L., Santangelo G., Foltynie T., Janvin C., Larsen JP., Barker RA., Emre M. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. (2010) Sep 21;75(12):1062-9.

Pagonabarraga J., Kulisevsky J., Llebaria G., García-Sánchez C., Pascual-Sedano B., Martinez-Corral M., Gironell A. PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease. Mov Disord. (2010) Mar 15;25(4):440-6.

Kulisevsky J., Pagonabarraga J. .Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord. (2009) Jun 15;24(8):1103-10. (review).

Llebaria G-, Pagonabarraga J-, Kulisevsky J-, García-Sánchez C-, Pascual-Sedano B-, Gironell A-, Martínez-Corral M. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord. (2008) Aug 15;23(11):1546-50.

Pagonabarraga J., Kulisevsky J., Llebaria G., García-Sánchez C., Pascual-Sedano B., Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord. (2008) May 15;23(7):998-1005.

Dr Alfons Macaya Ruiz

Cuenca-Leon E., Urbizu A., Boronat S., Solana E., Vendrell T., Vázquez E., Poca MA., Macaya A..Chiari Malformation Type I: Linkage to chromosome 16p13.3 in a large Spanish kindred. .Eur J Hum Genet (2009);17(S1).

Urbizu A., Cuenca-León E., Toma C., Sahuquillo J., Vendrell T., Cormand B., Poca MA., Macaya A. Chiari malformation type I and genes involved paraxial mesoderm development: a case control association study in the Spanish population (in preparation)

Dr Rafael Maldonado López

Dr Fernando Rodríguez de Fonseca

Dr Emilio Fernández Espejo

Trigo JM., Renoir T., Lanfumey L., Hamon M., Lesch KP. Robledo P. Maldonado R. 3,4- transporter methylenecli oxyme amphetamine self-administration is abolished in serotonin knockout mice. Biological Psychiatry, 62: 669-679 (2007). PMID: 17306775

Galán-Rodríguez B., Suárez J., Gonzalez-Aparicio R., Bermúdez-Silva FJ., Maldonado R., Robledo P., Rodríguez de Fonseca F., Fernández-Espejo E. Oleylethanolamide, an endogenous PPAR-a agonist, exerts partial and U-shaped neuroprotection of substantia nigra dopamine neurons. Neuropsychopharmacology March, (2009) 56(3): 653-64 Epub 2008

Plaza A., Berrendero F., Fernández-Espejo E., Rodríguez de Fonseca F., Maldonado R., Robledo P. Effects of the endogenous PPAR-a agonist, oleylethanolamide on MDMA-induced cognitive deficits in mice. Neuropsychoparmacology. Synapse (2010) May 64: (5) 379-84

Alvarado M., Goya P., Macías-González M., Pavón FJ., Serrano A., Jagerovic N., Elguero J., Gutiérrez-Rodríguez A., García-Granda S., Suardíaz M., Rodríguez de Fonseca F. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorganic & Medicine Chemistry, (2008) Dec 1;16(23):10098-105. Epub 2008 Oct 14. PMID: 18952442

Fernandez-Espejo E, Ramiro-Fuentes S., Rodriguez de Fonseca F. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience, (2009) Dec 1; 164(2):667-75. Epub 2009 Aug 18. PMID: 19698765

Cano C., Páez JA., Goya P., Serrano A., Pavón J., Rodríguez de Fonseca F., Suardíaz M., Martín MI. Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. European Journal of Medicinal Chemistry, (2009) Dec; 44(12):4889-95. Epub 2009 Aug 12. PMID: 19762126

Orejarena MJ., Lanfumey L., Maldonado R., Robledo P. Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour. International Journal of Neuropsychopharmacology, (2010) Oct; 14:1-14. [Epub ahead of print]. PMID:20942998

Almeida B., Joglar J., Luque Rojas MJ., Decara JM., Bermúdez-Silva FJ., Macias-González M., Fitó M., Romero-Cuevas M., Farré M., Covas MI., Rodríguez de Fonseca F., de la Torre R. Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties. ChemMedChem, (2010) Oct 4; 5(10):1781-7. PMID: 20718074

Serrano A., Pavón FJ., Tovar S., Casanueva F., Señarís R., Diéguez C., de Fonseca FR. Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake. Neuropharmacology, (2011) Mar; 60(4):593-601. Epub 2010 Dec 21. PMID: 21172362

Gonzalez-Aparicio R., Flores JA., Tasset I., Tunez I., Fernandez-Espejo E. Mice lacking the PPAR-alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron decline over life. Neuroscience. (2011) ([Epub ahead of print) PubMed PMID: 21463665

Fernández-Castillo N., Orejarena MJ., Ribasés M., Casas M., Robledo P., Maldonado R., Cormand B. Active and passive MDMA (‘ecstasy’) intake induces differential transcriptional changes in the mouse brain. Genes Brain and Behavior. (under 2nd review)

González-Aparicio R., Galán-Rodríguez B., Serrano A., Pavón FJ., Parsons LH., Maldonado R., Robledo P., Rodríguez de Fonseca F., Fernández-Espejo E. Systemic oleoylethanolamide exerts dose-dependent neuroprotection of the nigrostriatal circuit in experimental Parkinsonism. Psychopharmacology. (submitted)

Moreno-Santos I., Romero-Cuevas M., Suardiaz M., Pavón J., Serrano A., Cano C., Goya P., Rodríguez de Fonseca F., Macías-Gonzalez M. Sulfamide analogs of oleoylethanolamide as PPARalpha agonist by biological and computational analyses. Journal of Biological Chemistry. (submitted)

Rodriguez de Fonseca F., Macías-González M., Serrano A., Goya P., Alvarado M., Helguero J., Jagerovic N. Pyrazole derivatives of fatty acid amides as PPAR-alpha specific receptor activators, preparation methods and thereof use of them. WO2009/050318 A1 (Patent). Data de prioritat: 15 Octubre 2007.

Rodríguez de Fonseca F., Suárez Pérez J., Romero-Cuevas M., Fernández-Espejo E., Goya P., Páez Prósper JA. Uso de derivados de sulfamidas como neuroprotectores. P201130486 (Patent). Data de prioritat: 30 Març 2011.

Dr Maria Josefa Martí Domènech

Compta Y., Martí MJ., Ibarretxe-Bilbao N., Junqué C., Valldeoriola F., Muñoz E., Ezquerra M., Ríos J., Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009); 24: 2203-10.

Compta Y., Santamaria J., Ratti L., Tolosa E., Iranzo A., Muñoz E., Valldeoriola F., Casamitjana R., Ríos J., Marti MJ. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain (2009);132: 3308-17.

Compta Y., Ezquerra M., Muñoz E., Tolosa E., Valldeoriola F., Rios J., Cámara A., Fernández M., Buongiorno MT., Marti MJ. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low CSF β-amyloid in Parkinson disease. Neurosci Lett (2011); 487: 169-73

Compta Y., Ibarretxe-Bilbao N., Junque C., Bargallo N., Braga-Pereira J., Valldeoriola F., Muñoz E., Tolosa E., Marti MJ. τ and phospho-τ cerebrospinal levels correlate with temporal and frontal gray matter reduction in Parkinson’s disease and Parkinson’s disease with dementia. (in preparation)

Compta Y., Bargallo N., Tolosa E., Valldeoriola F., Muñoz E., Rios J., Martí MJ. Posterior white matter hyperintensities are associated with low CSF β-amyloid in Parkinson’s disease. (in preparation)

Compta Y., Ibarretxe-Bilbao N., Junque C., Camara A., Pont C., Buongiorno MT., Valldeoriola F., Tolosa E., Muñoz E,, Bargallo N,, Rios J,, Martí MJ. Association between CSF τ and amyloid-β markers with neuropsychological, morphometric and clinical outcomes in Parkinson’s disease: a longitudinal study. (in preparation)

Dr Rafael Martínez Poveda

Miró Andreu G., Martínez Poveda R., Cano Orgaz A., Solsona Durán JF., Solsona Perlasia M., Yébenes Reyes JC., Portugués Martínez G., Serra Prat M. Advanced Directives´s knowledge and performance related factors in Multiple Sclerosis´s patient. Comunicació al 18th Meeting of the European Neurological Society. 7-11 de Juny de 2008, Nice, France. J Neurol (2008) 255 (Suppl 2):80.

Dr Montserrat Milà Recasens

Rodriguez-Revenga L., Madrigal I., Alegret M., Santos M., Míla M. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet. (2008); 18: 153-155

Rodriguez-Revenga L., Santos MM., Sánchez A., Pujol M., Gómez-Anson B., Badenas C., Jiménez D., Madrigal I., Mila M. Screening for FXT AS in 95 Spanish patients negative for Huntington disease. Genet Test. (2008); 12: 135-138

Mila M., Madrigal I., Kulisevskye J., Pagonabarragae J., Gomez B., Sáncheza A., Rodríguéz-Revenga L. Síndrome de Temblor-Ataxia (FXTAS): un nuevo tipo de ataxia cerebelosa asociada a los portadores del síndrome X frágil. Med Clin Barcelona (accepted)

Pagonabarraga J., López-Mourelo O., Rodriguez-Revenga L., Xunclà M., Gómez-Ansón B., Milà M., Kulisevsky J. Reported hearing impairment in FXTAS. (submitted)

Xunclà M., Badenas C., Domínguez M., Rodríguez-Revenga L., Madrigal I., Jiménez L., Soler A., Borrell A., Sánchez A., Milà M. Fragile X syndrome prenatal diagnosis, parental attitudes and reproductive responses. Reprod Biomed Online. (2010) Oct; 21(4):560-5. Epub 2010 Jun 16

Rodriguez-Revenga L., Pagonabarraga J., Gómez-Anson B., López-Mourelo O., Xunclà M., Milà M. Motor and mental dysfunction in women with FXTAS: two families with mother-daughter transmission. Neurology. (2010) Oct 12;75(15):1370-6.

Rodriguez-Revenga L., Madrigal I., Pagonabarraga J., Xunclà M., Badenas C., Kulisevsky J., Gomez B., Milà M. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. (2009); 17: 1359-1362.

Milà M., Madrigal I., Kulisevsky J., Pagonabarraga J., Gómez B., Sánchez A., Rodríguez-Revenga L. Fragile X tremor ataxia syndrome (FXTAS): a new kind of spinocerebelar ataxia associated to fragile X syndrome premutation carriers. Med Clin (Barc) (2009);133: 252-254.

Premutation alleles in the FMR1 gene are associated with fibromyalgia. (in preparation)

Dr Pura Muñoz Cánoves

Suelves M., Vidal S., Serrano AL., Tjwa M., Roma J., López-Alemany R., Luttun A., Martínez de Lagrán M., Díaz MA., Jardí M., Roig M., Dierssen M., Dewerchin M., Carmeliet P., Muñoz¬Cánoves P. uPA deficiency exacerbates muscular dystrophy in mdx mice. J. Cell Biol. 178: (2007)

Perdiguero E., Ruiz-Sonilla V., Gresh L., Hui L., Sallestar E., Sousa-Victor P., Saeza-Raja S., Jardi M., Sosch-Comas A., Esteller M., Caelles C., Serrano AL., Wagner EF., Munoz-Canoves P. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 26:1245-56, (2007)

Perdiguero E., Ruiz-Sonilla V., Serrano AL., Muñoz-Cánoves P. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: The p38alpha-JNK Connection. Cell Cycle : 1298-303, (2007)

Vidal S., Serrano AL., Tjwa M., Suelves M., Ardite E., De Mori R., Saeza S., Martínez de Lagrán M., Ruiz-Sonilla V., Jardí M., Gherardi R.; Degen J., Christov C., Dierssen M., Dewerchin M., Carmeliet P., Muñoz-Cánoves P. Fibrinogen drives dystrophic muscle fibrosis via a TGFb/aiternative macrophage activation pathway. Genes & Development, 22:1747-52, (2008)

Serrano AL., Saeza-Raja S., Perdiguero E., Jardí M., Muñoz-Cánoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 7:33-44, (2008)

Serrano AL., Jardi M., Suelves M., Klotman PE., Muñoz-Cánoves P. HIV-1 transgenic expression in mice induces selective atrophy of fast-glycolytic skeletal muscle fibers. Front Biosci. 13:2797-805, (2008)

Ruiz-Sonilla V., Perdiguero E., Gresh L., Serrano AL., Zamora M., Sousa-Victor P., Jardí M., Wagner EF., Muñoz-Cánoves P. Efficient adult skeletal muscle regeneration in mice deficient in p38beta, p38gamma and p38delta MAP kinases. CellCycle Z:2208-14, (2008)

Perdiguero E., Muñoz-Cánoves P. Transcriptional regulation by the p38 MAPK signaling pathway in mammalian cells. Volume on SAPKs. Chapter by the Authors. Topics in Current Genetics. (2008) Posas F & Nebreda AR, Editors

Vidal B., Serrano AL., Tjwa M., Suelves M., Ardite E., De Mori R., Baeza B., Martínez de Lagrán M., Ruiz-Bonilla V., Jardí M., Gherardi R.; Degen J., Christov C., Dierssen M., Dewerchin M., Carmeliet P., Muñoz-Cánoves P Fibrinogen drives dystrophic muscle fibrosis via a TGFb/alternative macrophage activation pathway. Genes & Development, 22:1747-52, (2008).

Serrano AL., Muñoz-Cánoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Experimental Cell Research, 18:3050-8, (2010)

Serrano AL., Mann CJ., Vidal B., Ardite E., Perdiguero E., Muñoz-Cánoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Current Topics in Developmental Biology (in press, 2011)

Ardite E., Perdiguero E., Vidal E., Gutarra S., Serrano AL., Muñoz-Cánoves P. PAI-1-regulated TGFbeta defines a novel fibrogenic pathway in muscular dystrophy. Nature Medicine, (in revision 2011). Manuscript # NMED-A54436)

Serrano AL., Jardi M., Suelves M., Klotman PE., Muñoz-Cánoves P. HIV-1 transgenic expression in mice induces selective atrophy of fast-glycolytic skeletal muscle fibers. Front Biosci. 13:2797-805, (2008)

Perdiguero E., Muñoz-Cánoves P. Volume on "SAPKs". Chapter by the Authors: Transcriptional regulation by the p38 MAPK signaling pathway in mammalian cells. Topics in Current Genetics. (2008) (Posas F & Nebreda AR, Editors)

Perdiguero E., Sousa-Victor P., Ballestar E., Muñoz-Cánoves P. Epigenetic regulation of myogenesis. Epigenetics 4:541-50, (2009)

Cuadrado A., Corrado N., Perdiguero E., Lafarga V., Muñoz-Cánoves P., Nebreda AR. Essential role of p18Hamlet/SRCAP-mediated histone H2A.Z chromatin incorporation in muscle differentiation. EMBO J. 12:2014-25, (2010)

Dr Mercè Pallàs Lliberia

Dr Gemma Casadesús Rierola

Tajes M., Gutierrez-Cuesta J., Folch J., Ferrer L., Caballero S., Smith MA., Casadesl Js G., Camins A. and Pallas M. Lithium treatment prevents tau kinases activity in a murine model of senescence. Journal of Neurophathology and Experimental Neurology 67(6): 612-23

Pizarro JG., Yeste-Velasco M., Esparza JL., Verdaguer E., Pallas M., Camins A., Folch J. The antiproliferative activity of melatonin in S65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J Pineal Res. (2008) (in press)

Yeste-Velasco M., Alvira D., Sureda FX., Rimbau V., Forsby A., Palias M., Camins A., Folch J. DNA low-density array analysis of colchicine neurotoxicity in rat cerebellar granular neurons. Neurotoxicology. (2008) 29(2):309-317

Pallas M., Verdaguer E., Tajes M., Gutierrez-Cuesta J., Camins A. Modulation of sirtuins: new targets for antiageing. Recent Patents CNS Drug Discov. (2008) 3(1):61-9

Camins A., Verdaguer E., Folch J., Seas-Zarate C., Canudas AM., Pallas M. Inhibition of ataxia telangiectasia-p53-E2F-1 pathway in neurons as a target for the prevention of neuronal apoptosis. Curr Drug Metab. (2007) 8(7):709-15 (review)

Alvira D., Ferrer L., Gutierrez-Cuesta J., Garcia-Castro S., Pallas Ml, Camins A. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord (2007)

Alvira D., Yeste-Velasco M., Folch J., Casadesús G., Smith MA., Palias M., Camins A. Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons. J Neurosci Res. (2007) 85i14):3079-88

Chou E., Smith MA., Camins A., Pallas-Liberia M., Casadesus G. Validation of the age-accelerated mouse model (SAMP8) to study longevity associated signaling mechanisms (2008). CWRU Research ShowCASE, Abs. 315

Smith MA., Sanchez J., Lau, A., Tarkowsky SM., Ziats A., Camins A., Pallas-Lliberia M. and Casadesus G. (2008). The senescence accelerated mouse (SAMP8) as a model to determine early pathological changes in Alzheimer disease. J. Neurochem., 104 (Suppl. 1),21

Tajes M., Gutierrez-Cuesta J., Folch J., Ferrer L., Caballero B., Smith MA., Casadesus G., Camins A. and Pallas M. Lithium treatment prevents tau kinases activity in a murine model of senescence. JNEN (accepted)

Pizarro JG., Yeste-Velasco M., Rimbau V., Casadesús G., Smith MA., Pallas M., Folch J., Camins A. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. Int J Dev Neurosci. 2008 May-June;26(3-4):269,276 Epub 2008 Feb 8

Pelegrí C., Canudas AM., del Valle J., Casadesus G., Smith MA., Camins A., Palias M., Vilaplana J. Increased permeability of blood-brain barrier on the hippoc.ampus of a murine model of senescence. Mech Ageing Dev. 2007 Sep;128(9):522-8. Epub 2007 Ju110

Alvira D., Yeste-Velasco M., Folch J., Casadesús G., Smith MA., Pallas M., Camins A. Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons. J Neurosci Res. 2007 Nov 1 ;85(14):3079-88

García-Matas S., Gutierrez-Cuesta J., Coto-Montes A., Rubio-Acero R., Diez-Vives C.: Camins A., Palias M., Sanfeliu C., Cristófol R. Dysfunction of astrocytes in senescence-accelerated mice SAMP8 reduces their neuroprotective capacity. Aging Cell. (2008) 7(5):630-40.

Gutierrez-Cuesta J., Tajes M., Jiménez A., Coto-Montes A., Camins A., Pallas M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J Pineal Res. (2008) 45(4):497-505.

Pallas M., Pizarro JG., Gutierrez-Cuesta J., Crespo-Biel N., Alvira O., Tajes M., Yeste-Velasco M., Folch J., Canudas AM., Sureda FX., Ferrer I., Camins A. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience. (2008) ;154(4):1388-1397

Caballero B., Vega-Naredo I., Sierra V., Huidobro-Femández C., Soria-Valles C., De Gonzalo-Calvo O., Tolivia O., Pallás M., Camins A., Rodríguez-Colunga MJ., Coto-Montes A. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. J Pineal Res. (2009) 46(1 ):1 06-14.

Del Valle J., Duran-Vilaregut J., Manich G., Camins A., Palias M., Vilaplana J., Pelegrí C. Time-course of blood-brain barrier disruption in senescence-accelerated mouse prone 8 (SAMP8) mice. Int J Dev Neurosci. (2009) Feb;27(1):47-49

Tajes M, Yeste-Velasco M, Zhu X, Chou SP, Smith MA, Palias M, Camins A,Casadesús G (2009). Activation of Akt by lithium: Pro-survival pathways in aging. Mechanisms of Agening and Development (2009) 30(4):253-61.

Chang J., Bryan K., Reeves J., Mudd JC., Zhu,X., Smith M., Camins A., Casadesus G. Effects of resveratrol and pterostilbene on cognition, synaptic plasticity and AD pathology in the age-accelerated SAMP8 mouse. 2009 CWRU Research ShowCASE, 435. (2009)

Kim T., Bryan K., Reeves J., Mudd J., Lee HG., Smith MA., Camins A., Pallas M., Shim S., Casadesus G. Low does of lithium chloride improve cognition and neuronal function in the age-accelerated SAMP8 mouse. 2009 CWRU Research ShowCASE, in press (2009)

Pallas M.; Camins A.; Smith MA.; Perry G.; Lee HG.; Casadesus G. From aging to Alzheimer's disease: unveiling 'the switch' with the senescence-accelerated mouse model (SAMP8). Journal of Alzheimer's Disease 15(4): 615-624. (2008)

Camins A., Crespo-Biel N., Junyent F., Verdaguer E., Canudas AM., Pallàs M. Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. Current Drug Metabolism. 10 (5): 433- 447. (2009)

Pizarro JG.; Folch J.; Esparza JL.; Jordan J.; Pallàs M.; Camins A. A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286 Journal of Cellular and Molecular Medicine. 13(9B): 3906-3917. (2009)

Tajes M.; Gutierrez-Cuesta J.; Ortuño-Sahagun D.; Camins A.; Pallàs M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. Journal of Pineal Research 47(3):228- 237. (2009)

Camins A.; Verdaguer E.; Junyent F.; Yeste-Velasco M.; Pelegrí C.; Vilaplana J.; Pallàs, M. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosciences and Therapeutics. 15 (4): 333-344 (2009)

Camins A., Sureda FX., Junyent F., Verdaguer E., Folch J., Beas-Zarate C., Pallas M. An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders. Expert Opin Investig Drugs. 19(5), 587- 604, (2010)

Pizarro JG., Verdaguer E., Ancrenaz V., Junyent F., Sureda F., Pallàs M., Folch J., Camins A. Resveratrol Inhibits Proliferation and Promotes Apoptosis of Neuroblastoma Cells: Role of Sirtuin 1. Neurochem Res. 36 (2) 187-194, (2011)

Camins A.; Sureda FX.; Junyent F.; Verdaguer E.; Folch J.; Beas-Zarate C.; Pallas M. An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders. Expert Opinion On Investigational Drugs. 19 (5) 587- 604. (2010)

Tajes,M.; Gutierrez-Cuesta J..; Folch J.; Ortuño-Sahagun D.; Verdaguer E.; Jiménez A.; Junyent F.; Lau A.; Camins A.; Pallàs M. Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Experimental Gerontology 45 (9): 702- 710. (2010)

Dr Marçal Pastor Anglada

Pinilla-Macua I., Aymerich I., Huber-Ruano I., Casado FJ., Pastor-Anglada M. The high-affinity adenosine transporter, rCNT2, requires dual sorting signals for its trafficking to plasma membrane. Purinergic Signalling 6:66, Suppl. 1, (2010)

Medina-Pulido L., Molina-Arcas M., Casado FJ., Burgaya F., Pastor-Anglada M. Purinergic regulation of the nucleoside transporter rCNT2 in rat neuronal model. Purinergic Signalling 6:66, Suppl. 1, (2010)

Dr Gaietà Permanyer Miralda

Gallofré M., Abilleira S., Álvarez-Sabín J., Chamorro A., Dávalos A., Martí-Fábregas J., Roquer J., Serena J. Organisation of a population-based acute stroke care model in Catalonia. Cerebrovasc Dis (2008) ;25(suppl 2):100. 17th European Stroke Conference. Nice, May 13-16, 2008, France.

Abilleira S., Ribera A., Permanyer G., Salvat-Plana M., Gallofré M. Determinantes de la demora en la alerta tras el ictus. LXI Reunión Anual de la Sociedad Española de Neurología. Barcelona, noviembre de 2009. Neurología (2009); 24(8):598.

Ribera A., Abilleira S., Permanyer G., Salvat-Plana M., Gallofré M.; on behalf of The Catalan Stroke Code Group (Cat-SC). Strengths and Weaknesses of a region-wide model of acute stroke care. The Catalan Stroke Code Study. 19th European Stroke Conference. Barcelona, Spain, May 25-28, 2010. Cerebrovasc Dis (2010); 29 (suppl 2).

Abilleira S., Dávalos A., Chamorro A., Álvarez-Sabín J., Gallofré M.; on behalf of the Catalan Stroke Code and Thrombolysis Group (Cat-SCT). Outcomes of intravenous thrombolysis in routine practice after implementation of a region-wide acute stroke care model in Catalonia. The Catalan Stroke Code and Thrombolysis Study. 19th European Stroke Conference. Barcelona, Spain, May 25-28, 2010. Cerebrovasc Dis (2010) ;29 (suppl 2).

Gallofre M., Abilleira S., Tresserras R., De la Puente ML. El Plan Director para la atención de la enfermedad cerebrovascular en Cataluña. Med Clin (Barc). (2009);133(15):589–593.

Abilleira S., Lucente G., Ribera A., Permanyer-Miralda G., Gallofré M. Patient-related Features Associated with a Delay in Seeking Care After Stroke. Eur J Neurol. (2010); doi:10.1111/j.1468-1331.2010.03258.

Abilleira S., Dávalos A., Chamorro A., Álvarez-Sabín J., Ribera A., Gallofré M.; on behalf of the Catalan Stroke Code and Thrombolysis Study group (Cat-SCT). Outcomes of intravenous thrombolysis after dissemination of the Stroke Code and designation of new referral hospitals in Catalonia. The Cat-SCT monitored Study. Stroke. (2011) (in press).

Dr Antoni Rodríguez Fornells

Dr Thomas Münte

Dr Carles Grau Fonollosa

Schneider S., Schonle PW., Altenmüller E., Münte TF. (2007). Using musical instruments to improve motor skill recovery following a stroke. J Neurol. 254(10): 1339-46

Fuentemilla LI., Marco-Pallarés J., Münte TF., Grau C. Theta EEG oscillatory activity and auditory change detection. Brain Research (in press)

Grau C., Fuentemilla LI., Marco-Pallarés J. Functional neural dynamics underlying auditory event-related N1 and N1 suppression response. Neuroimage. (2007). 36:522-531

Schneider S., Marco-Pallarés J., Münte TF., Altenmüller E. Neural reorganization. induced by music-supported therapy in stroke patients with motor dysfunctions. (submitted)

Schneider, S. Objektivierung eines musikunterstützten Trainings motorischer Funktionen nach Schlaganfall (Taschenbuch). Sierke Verlag. (2007) book Rodriguez-Fornells A. Music-supported therapy induced plasticity in the sensorimotor cortex in chronic stroke patients. Congress, The Neurosciences and Music IV, Learning and Memory. June 9-12, (2011). Edinburgh (this presentation will be published in 2012 at the Annals of the New York Academy of Sciences)

Ripollés P., Marco-Pallarés J., Miró J., de Diego-Balaguer R., Falip M., Juncadella M., Rubio F., Rodriguez-Fornells A. Analysis of automated methods for spatial normalisation of lesioned brains. Neuroimage (submitted).

Rojo N., Amengual J., Camara E., Juncadella M., Rubio F., Schneider S., Marco-Pallares J., Veciana C., Montero J., Grau C., Münte TF., Rodriguez-Fornells A. Music-Supported Therapy induces plasticity in the sensorimotor cortex in stroke: a single-case study using multimodal imaging (fMRI-TMS). Brain Injury (in press). (2011).

Schneider S., Münte TF., Rodriguez-Fornells A., Sailer M., Altenmüller E. Music-Supported Training is more efficient than functional motor training for recovery of fine motor skills in stroke patients. Music Perception, 27, 271–280. (2010).

Altenmüller E., Marco-Pallares J., Münte TF., Schneider S. Neural Reorganization Underlies Improvement in Stroke-induced Motor Dysfunction by Music-supported Therapy. Annals of the New York Academy of Sciences 1169: 395–405 (2009).

Dr Antonio Luis Serrano Sánchez

Dr Lucía Tabares Domingo

Ruiz-Bonilla V., Perdiguero E., Gresh L., Serrano AL., Zamora M., Sousa-Victor P., Jardí M., Wagner EF., Muñoz-Cánoves P. Efficient adult skeletal muscle regeneration in mice deficient in p38beta, p38gamma and p38delta MAP kinases. Cel! Cycle. (2008) JuI15;7(14):2208-14

Vidal S., Serrano AL., Tjwa M., Suelves M., Ardite E., De Mori R, Saeza-Raja-S., Martínez de Lagrán M., Lafuste P., Ruiz-Sonilla V., Jardí M., Gherardi R., Christov C., Dierssen M., Carmeliet P., Degen JL., Dewerchin M., Muñoz-Cánoves P. Fibrinogen drives dystrophic muscle fibrosis via a , TGFbeta/alternative macrophage activation pathway. Genes Dev. (2008) JuI1;22(13):1747-52

Serrano AL., Saeza-Raja S., Perdiguero E., Jardí M., Muñoz-Cánoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cel! Metab. (2008) Jan;7(1):33-44

Serrano AL., Jardi M., Suelves M., Klotman PE., Munoz-Canoves P. HIV-1 transgenic expression in mice induces selective atrophy of fast-glycolytic skeletal muscle fibers. Front Biosci. (2008) Jan 1; 13:2797 -805

Suelves M., Vidal B., Serrano AL., Tjwa M., Roma J., López-Alemany R., Luttun A., Martínez de Lagrán M., Díaz MA., Jardí M., Roig M., Dierssen M., Dewerchin M., Carmeliet P., Muñoz-Cánoves P. uPA deficiency exacerbates muscular dystrophy in mdx mice. J. Cell Biol. 178: (2007)

Serrano AL., Muñoz-Cánoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Experimental Cell Research, 18:3050-8, (2010)

Serrano AL., Mann CJ., Vidal B., Ardite E., Perdiguero E., Muñoz-Cánoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Current Topics in Developmental Biology (in press, 2011)

Ardite E., Perdiguero E., Vidal E., Gutarra S., Serrano AL., Muñoz-Cánoves P. PAI-1-regulated TGFbeta defines a novel fibrogenic pathway in muscular dystrophy. (Nature Medicine, (in revision 2011). Manuscript # NMED-A54436)

Guerrero L., Marco-Ferreres R., Serrano AL., Arredondo JJ., Cervera M. Secondary enhancers synergise with primary enhancers to guarantee fine-tuned muscle gene expression. Dev Biol. Jan (2010) (1):16-28.

Perdiguero E., Ruiz-Bonilla V., Gresh L., Hui L., Ballestar E., Sousa-Victor P., Baeza-Raja B., Jardi M., Bosch-Comas A., Esteller M., Caelles C., Serrano AL., Wagner EF., Muñoz-Cánoves P. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 26:1245-56, (2007)

Perdiguero E., Ruiz-Bonilla V., Serrano AL., Muñoz-Cánoves P. Genetic Deficiency of p38alpha Reveals its Critical Role in Myoblast Cell Cycle Exit: The p38alpha-JNK Connection. Cell Cycle 6: 1298-303, (2007)

Dr Francisco Javier Setoain Perego

Setoain FJ. Validation of an automatic dose injection system for ictal SPECT in epilepsy.: Eur J Nucl Med Mol Imaging al Març (2011) (sent)

Dr Eduard Tolosa Sarró

Dr Pau Pastor Muñoz

Gaig C., Tolosa E. When does Parkinson’s disease begin?. Movement Disorders 2009;24 Suppl 2:S656-64

Valldeoriola F., Gaig C., Muxí A., Navales I., Paredes P., Lomeña F., De la Cerda A., Buongiorno M., Ezquerra M., Santacruz P., Martí MJ., Tolosa E. (123)I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.. J Neurol. (2011) Jan 8. (Epub ahead of print)

Tolosa E., Pont-Sunyer C. Progress in defining the pre-motor phase of Parkinson’s disease. J neurol Sci (in press.)

Dr Antoni Turon Estrada

Garre-Olmo J., Planas-Pujol X., López-Pousa S., Weiner MF., Turon-Estrada A., Juvinyà D., Ballester D., Vilalta-Franch J. Cross-cultural adaptation and psychometric validation of a Spanish version of the Quality of Life in Late-Stage Dementia (QUALID) Scale. Quality of Life Research (2010);19(3):445-53.

Turon A. Environmental determinants of quality of life in advanced dementia (in preparation)